1. Home
  2. ABP vs CTXR Comparison

ABP vs CTXR Comparison

Compare ABP & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABP
  • CTXR
  • Stock Information
  • Founded
  • ABP 2004
  • CTXR 2007
  • Country
  • ABP United States
  • CTXR United States
  • Employees
  • ABP N/A
  • CTXR N/A
  • Industry
  • ABP Biotechnology: Pharmaceutical Preparations
  • CTXR Biotechnology: Pharmaceutical Preparations
  • Sector
  • ABP Health Care
  • CTXR Health Care
  • Exchange
  • ABP Nasdaq
  • CTXR Nasdaq
  • Market Cap
  • ABP 15.5M
  • CTXR 14.6M
  • IPO Year
  • ABP N/A
  • CTXR N/A
  • Fundamental
  • Price
  • ABP $0.21
  • CTXR $1.53
  • Analyst Decision
  • ABP Strong Buy
  • CTXR Strong Buy
  • Analyst Count
  • ABP 1
  • CTXR 3
  • Target Price
  • ABP $4.00
  • CTXR $53.00
  • AVG Volume (30 Days)
  • ABP 5.6M
  • CTXR 6.7M
  • Earning Date
  • ABP 08-18-2025
  • CTXR 08-11-2025
  • Dividend Yield
  • ABP N/A
  • CTXR N/A
  • EPS Growth
  • ABP N/A
  • CTXR N/A
  • EPS
  • ABP N/A
  • CTXR N/A
  • Revenue
  • ABP $183,000.00
  • CTXR N/A
  • Revenue This Year
  • ABP N/A
  • CTXR N/A
  • Revenue Next Year
  • ABP N/A
  • CTXR N/A
  • P/E Ratio
  • ABP N/A
  • CTXR N/A
  • Revenue Growth
  • ABP 88.66
  • CTXR N/A
  • 52 Week Low
  • ABP $0.15
  • CTXR $0.65
  • 52 Week High
  • ABP $11.19
  • CTXR $26.25
  • Technical
  • Relative Strength Index (RSI)
  • ABP N/A
  • CTXR 68.44
  • Support Level
  • ABP N/A
  • CTXR $0.76
  • Resistance Level
  • ABP N/A
  • CTXR $1.45
  • Average True Range (ATR)
  • ABP 0.00
  • CTXR 0.31
  • MACD
  • ABP 0.00
  • CTXR 0.06
  • Stochastic Oscillator
  • ABP 0.00
  • CTXR 47.63

About ABP Abpro Holdings Inc Common Stock

Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.

Share on Social Networks: